https://www.yiliao.com/index.php?action=history&feed=atom&title=G2032R
G2032R - 版本历史
2026-04-21T15:11:12Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=G2032R&diff=315580&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-24T15:50:40Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>G2032R</strong> 是 <strong>[[ROS1]]</strong> 原癌基因酪氨酸激酶结构域第 2032 位甘氨酸（Glycine）被精氨酸（Arginine）取代的错义突变。它是 ROS1 阳性<strong>[[非小细胞肺癌]]</strong>（NSCLC）患者接受第一代 TKI（<strong>[[克唑替尼]]</strong>）或第二代 TKI（<strong>[[恩曲替尼]]</strong>）治疗后最常见、最棘手的<strong>[[获得性耐药]]</strong>机制，约占耐药病例的 30%-40%。该位点位于激酶的<strong>[[溶剂前沿区]]</strong>（Solvent Front），突变引入的大侧链基团造成显著的空间位阻，阻止药物结合。幸运的是，第四代（下一代）ROS1 抑制剂——<strong>[[瑞普替尼]]</strong>（Repotrectinib）和<strong>[[他雷替尼]]</strong>（Taletrectinib）凭借精巧的分子设计，成功克服了 G2032R 耐药。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ROS1 G2032R</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Solvent Front Mutation (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:G2032R_steric_hindrance_mechanism.png|100px|G2032R 造成的空间位阻]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">ROS1 耐药之王</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">所属基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ROS1]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">突变类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[溶剂前沿突变]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发生率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">耐药后 ~40%</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #64748b;">[[克唑替尼]]<br>[[恩曲替尼]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">敏感药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[瑞普替尼]]</strong><br><strong>[[他雷替尼]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">检测方法</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">液体/组织 [[NGS]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">同源突变</th><br />
<td style="padding: 6px 12px; color: #0f172a;">ALK [[G1202R]]<br>RET [[G810]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：溶剂前沿的“路障”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
G2032R 的致病原理是经典的“空间位阻”效应，发生在激酶 ATP 结合口袋的溶剂前沿区（Solvent Front）。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>野生型 (G2032)：</strong><br />
<br>第 2032 位是<strong>甘氨酸</strong>（Glycine），这是侧链最小的氨基酸。克唑替尼和恩曲替尼利用这个空间，将庞大的分子结构延伸至溶剂区，从而获得高亲和力。</li><br />
<li style="margin-bottom: 12px;"><strong>突变型 (G2032R)：</strong><br />
<br>甘氨酸突变为<strong>精氨酸</strong>（Arginine）。精氨酸拥有一个带正电荷的巨大侧链。这个庞然大物直接占据了药物结合的空间，物理上将克唑替尼和恩曲替尼“顶”出了结合口袋，导致药物亲和力下降数千倍，临床表现为疾病进展。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床攻坚：下一代 TKI 的胜利</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">大环分子的降维打击</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
为了克服 G2032R，科学家设计了具有<strong>[[大环结构]]</strong>（Macrocycle）的分子，如瑞普替尼。其紧凑的球形结构能巧妙地避开精氨酸侧链的干扰，重新嵌入结合口袋。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物代系</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 35%;">代表药物</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">对 G2032R 疗效</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第一代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[克唑替尼]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>耐药</strong></td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第二代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[恩曲替尼]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>耐药</strong> (IC50 极高)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">第三代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[洛拉替尼]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;">有一定活性 (部分有效)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>第四代<br>(下一代)</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[瑞普替尼]]</strong><br>[[他雷替尼]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>高度敏感</strong><br>(TRIDENT-1 ORR 59%)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Awad MM, Katayama R, McTigue M, et al. (2013).</strong> <em>Acquired resistance to crizotinib from a mutation in CD74-ROS1.</em> <strong>[[New England Journal of Medicine]]</strong>. 2013;368(25):2395-2401.<br><br />
<span style="color: #475569;">[发现耐药]：首次报道了 G2032R 突变是克唑替尼治疗 ROS1 融合肺癌后的主要耐药机制，并揭示了其分子结构基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Drilon A, Camidge DR, Lin JJ, et al. (2024).</strong> <em>Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. 2024;390(2):118-131.<br><br />
<span style="color: #475569;">[TRIDENT-1]：瑞普替尼的关键确证性研究。结果显示，对于既往 TKI 治疗失败且携带 G2032R 突变的患者，瑞普替尼实现了 59% 的客观缓解率，确立了新标准。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Lin JJ, et al. (2020).</strong> <em>Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.</em> <strong>[[Clinical Cancer Research]]</strong>.<br><br />
<span style="color: #475569;">[耐药谱系]：系统分析了 ROS1 阳性患者的耐药图谱，指出 G2032R 是最常见的“关卡”，且常规药物难以攻克。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
G2032R · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">所属基因</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[ROS1]]</strong> (原癌基因)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">突变位置</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[溶剂前沿区]]</strong> (Solvent Front)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗突破</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[瑞普替尼]]</strong> (Repotrectinib) • [[他雷替尼]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类类比</td><br />
<td style="padding: 10px 15px; color: #334155;">ALK [[G1202R]] • RET [[G810]] • TRK [[G595R]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020